The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been ... It is also facing a class action suit alleging economic injury, as well as a third-party payer class action ...

The settlement arises amidst allegations that Zantac ... Price Action: SNY shares are up 1.02% at $48.45 during the premarket session on the last check Thursday.

GSK admitted no wrongdoing or liability in the settlements, and said they were in the best long-term interest of the company to avoid the risk of continuing litigation. GSK launched Zantac in 1981 ...

British pharmaceutical company GSK said on Wednesday that it has agreed to pay $2.3 billion to put an end to lawsuits in the United States alleging that its heartburn drug Zantac caused cancer.

That move led to tens of thousands of lawsuits against the drug's manufacturers. The previous year, UK doctors were told to stop prescribing four types of Zantac as a "precautionary measure".